FDA Vowes Improved Adverse Event Reporting With AEMS

The FDA announced today the launch of the FDA Adverse Event Monitoring System (AEMS).¹ This new unified platform is designed to consolidate the agency's previously fragmented and outdated reporting systems into a single, streamlined interface, improving post-market surveillance for all FDA authorized products. Officials say the transition marks the end of a "patchwork" era of safety surveillance.¹

Why Did the FDA Replace Its Legacy Adverse Event Reporting Systems?

The AEMS replaces a series of aging, disparate databases that FDA Commissioner Marty Makary, MD, MPH, described as "outdated and fragmented."¹ Historically, the agency managed approximately 6 million adverse event reports annually across seven different databases, a system that cost taxpayers roughly $37 million per year to operate.² These legacy systems—which included the FDA Adverse Event Reporting System, the Vaccine Adverse Event Reporting System, and the animal-focused Adverse Event Reporting System —often created "blind spots" in post-market surveillance.¹

"The team executed with perfection and delivered the biggest technical transformation in agency history," stated Chief AI Officer Jeremy Walsh, highlighting the aggressive schedule used to migrate these systems. By consolidating these resources, the FDA expects to realize $120 million in savings over the next five years.²

How Will Real-Time Adverse Event Reporting Change Industry Access to Safety Data?

Perhaps the most consequential change for pharmaceutical companies is the shift from quarterly data releases to real-time publication of adverse event reports.¹ Under the previous framework, the delay in data availability often led to a high volume of Freedom of Information Act requests from those seeking the latest safety information, ahead of quarterly reports.¹ The AEMS platform aims to significantly reduce this administrative burden by providing immediate access to reports, consistent with patient privacy protections.

For commercialization teams, this means a more dynamic environment for monitoring product lifecycles and benefit-risk profiles. The system’s unified platform is intended to enhance data quality through standardized reporting protocols and streamline the reporting process for both internal FDA staff and external stakeholders. Furthermore, the platform integrates AI-based redaction and digitization tools, which are expected to improve the speed and accuracy of case processing.¹

The scope of AEMS extends beyond traditional side-effect reporting. The FDA has designed the platform to serve as a centralized hub for managing consumer complaints, regulatory misconduct reports, and whistleblower submissions across all agency centers.¹ This comprehensive approach is intended to facilitate better trend identification across diverse product categories, supporting more timely regulatory decision-making.

As of the launch, the system already includes reports for drugs, biologics, vaccines, cosmetics, and animal food. By the end of May 2026, the agency plans to integrate all remaining product centers, including the Manufacturer and User Facility Device Experience for medical devices, the Human Foods Complaint System, and the Center for Tobacco Products Adverse Event Reporting System.¹

How Could AEMS Change Pharmacovigilance for Pharma Companies?

The rollout of AEMS is part of a broader mission to provide “radical transparency” into the safety of regulated products.¹ As the agency decommissions its legacy systems and migrates historical data to the new platform, it also plans to roll out enhanced application program interfaces (APIs) and advanced data analytics tools.¹ These enhancements are expected to further empower agency scientists and industry researchers to identify potential safety signals—such as patterns or clusters of events—that might indicate previously unknown risks.

For the pharmaceutical sector, the AEMS launch signifies a shift toward a more data-intensive and transparent regulatory landscape, where safety surveillance is no longer a quarterly look-back but a continuous, real-time process.

References

• US Food and Drug Administration. FDA launches new adverse event look-up tool. March 11, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-new-adverse-event-look-tool

1. Sunny M. US FDA launches unified platform to report drug side effects. Reuters. March 11, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-launches-unified-platform-report-drug-side-effects-2026-03-11/